SHORT-COURSE RADIOTHERAPY FOR OLDER PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER AND UNFIT FOR CHEMOTHERAPY: THE SOFT STUDY
Gerardo Rosati(Ospedale San Carlo), Giuseppe Giovinazzo(Ospedale San Carlo), Silvia Ortolani(Ospedale San Bortolo), Alessandro Parisi(Marche Polytechnic University), Giorgio Reggiardo(Data Management (Italy)), Alfonso De Stefano(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), V. Fanotto(University of Udine), Giuseppe Cicero(University of Palermo), Carmela Romano(Centro di Riferimento Oncologico della Basilicata), Fabrizio Tonetto(Ospedale Santa Maria della Misericordia di Udine), Chiara Carlomagno(Federico II University Hospital), Stefania Eufemia Lutrino(Ospedale A. Perrino), Vincenzo Ravo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Francesca Dapoto(Ospedale San Carlo), Angelo Restivo(University of Cagliari), Antonio Avallone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Giuseppe Aprile(Ospedale Santa Maria della Misericordia di Udine), Emanuela Dell’Aquila(Università Campus Bio-Medico), Valerio Argiolas(University of Cagliari), Alfredo Colombo
Cited by 0
Related Papers
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k